



# Medicine Supply Notification

MSN/2024/070

Quetiapine 150mg, 200mg, 300mg tablets

Tier 2 – medium impact\*

Date of issue: 06/06/2024

Link: [Medicines Supply Tool](#)

## Summary

- There are limited supplies of quetiapine 150mg, 200mg and 300mg tablets until late August 2024.
- Quetiapine 25mg, 50mg and 100mg tablets currently remain available and can support a partial increase in demand.
- Quetiapine XL prolonged release tablets (50mg, 150mg, 200mg, 300mg, 400mg and 600mg) remain available and can support a partial increase in demand.
- Quetiapine 20mg/ml oral suspension remains available and can support a partial increase in demand.
- Any updates to the supply of quetiapine tablets (any strengths) will be communicated via the Medicines Supply Tool.

## Actions Required

Clinicians should not initiate new patients on standard release quetiapine 150mg, 200mg and 300mg tablets until the supply issues resolve.

Where patients have insufficient supply of quetiapine 150mg, 200mg, 300mg tablets to last until the resupply date, clinicians should consider prescribing where available:

- quetiapine 25mg, 50mg or 100mg tablets, using the largest strength tablet(s) available to provide the required dose; or
- quetiapine XL prolonged-release tablets, adjusting the dose frequency to once daily, counselling patients on the change to formulation and dosing regimen, and to take the dose without food (see Supporting information); or
- quetiapine 20mg/ml oral solution, only where tablets are not appropriate ensuring there is no intolerance to the excipients; and
- if the above options are not considered appropriate, advice should be sought from specialists on alternative management options.

## Supporting information

### Clinical Information

Quetiapine is licensed for the treatment of schizophrenia, bipolar disorder, moderate to severe manic episodes in bipolar disorder, major depressive episodes in bipolar disorder, and for the prevention of recurrence of manic or depressed episodes in patients with bipolar disorder, who previously responded to quetiapine treatment.

\*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Although food has a minimal effect on quetiapine absorption in the immediate release (IR) formulations, consumption of a high-fat meal increases bioavailability of quetiapine in the XL formulation.

The IR tablets and oral suspension are administered twice a day with or without food across the indications, except in the treatment of major depressive episodes in bipolar disorder where the dose is administered once daily at bedtime.

The XL prolonged release tablets are administered once daily without food, at least one hour before a meal.

When switching patients from IR tablets to XL prolonged release tablets, the total daily dose of quetiapine is taken once daily; individual dosage adjustments may be necessary.

[Links to further information](#)

[SmPC quetiapine](#)

[BNF quetiapine](#)

[BNFC quetiapine](#)

## Enquiries

If you have any queries, please contact [DHSCmedicinesupplyteam@dhsc.gov.uk](mailto:DHSCmedicinesupplyteam@dhsc.gov.uk)